First-versus third-generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with brain metastases
Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs …
MX Li, H He, ZH Ruan, YX Zhu, RQ Li, X He, BH Lan… - BMC cancer, 2017 - Springer
Background Central nervous system (CNS) brain metastasis of advanced non-small cell
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 …
SJ Park, HT Kim, DH Lee, KP Kim, SW Kim, C Suh… - Lung cancer, 2012 - Elsevier
Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non‐small cell lung cancer
MS Ahluwalia, K Becker, BP Levy - The Oncologist, 2018 - academic.oup.com
Central nervous system (CNS) metastases are a common complication in patients with
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …
[HTML][HTML] Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
S Bhandari, N Dunlap, G Kloecker - Journal of Thoracic Disease, 2021 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations are present in 20–40% of non-small cell
lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC …
lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
A comparison between first-, second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer and …
S Caponnetto, O Cantale, A Friedlaender… - Journal of Molecular …, 2021 - mdpi.com
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer
WJ Kelly, NJ Shah, DS Subramaniam - Frontiers in oncology, 2018 - frontiersin.org
Lung cancer remains a leading cause of mortality with 1.69 million deaths worldwide.
Activating mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 …
Activating mutations in epidermal growth factor receptor (EGFR), predominantly exon 19 …
Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer
GL Ceresoli - Current Cancer Drug Targets, 2012 - ingentaconnect.com
Brain metastases (BM) are a common occurrence in patients with non-small cell lung cancer
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …
Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR …
Purpose This study was to determine whether combining blood-brain-barrier-penetrant
tyrosine kinase inhibitor (TKI), osimertinib, with intracranial radiotherapy (TKI+ RT) would …
tyrosine kinase inhibitor (TKI), osimertinib, with intracranial radiotherapy (TKI+ RT) would …